Answer
Capivasertib (Truqap) with fulvestrant is indicated for adults with HR-positive, HER2-negative (IHC 0/1+ or IHC 2+/ISH−), locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following recurrence or progression on or after an endocrine-based regimen.
Sources for this answer
- Truqap 160 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 5Document updated
Sources checked